Hydroxytyrosol

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Hydroxytyrosol
Accession Number
DB12771
Type
Small Molecule
Groups
Investigational
Description

Hydroxytyrosol has been used in trials studying the prevention of Breast Cancer.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
QEU0NE4O90
CAS number
10597-60-1
Weight
Average: 154.1632
Monoisotopic: 154.062994186
Chemical Formula
C8H10O3
InChI Key
JUUBCHWRXWPFFH-UHFFFAOYSA-N
InChI
InChI=1S/C8H10O3/c9-4-3-6-1-2-7(10)8(11)5-6/h1-2,5,9-11H,3-4H2
IUPAC Name
4-(2-hydroxyethyl)benzene-1,2-diol
SMILES
OCCC1=CC=C(O)C(O)=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbciximabHydroxytyrosol may increase the anticoagulant activities of Abciximab.Approved
AcemetacinThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Hydroxytyrosol.Approved, Experimental, Investigational
AcenocoumarolHydroxytyrosol may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Acetylsalicylic acid.Approved, Vet Approved
AloxiprinThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Aloxiprin.Experimental
AlprostadilAlprostadil may increase the antiplatelet activities of Hydroxytyrosol.Approved, Investigational
AlteplaseHydroxytyrosol may increase the anticoagulant activities of Alteplase.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Aminosalicylic Acid.Approved
AnagrelideHydroxytyrosol may increase the anticoagulant activities of Anagrelide.Approved
AncrodHydroxytyrosol may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideAndrographolide may increase the antiplatelet activities of Hydroxytyrosol.Investigational
AnistreplaseHydroxytyrosol may increase the anticoagulant activities of Anistreplase.Approved
Antithrombin III humanHydroxytyrosol may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Apixaban.Approved
ArdeparinHydroxytyrosol may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanHydroxytyrosol may increase the anticoagulant activities of Argatroban.Approved, Investigational
AstaxanthinHydroxytyrosol may increase the anticoagulant activities of Astaxanthin.Investigational
AzelastineAzelastine may increase the antiplatelet activities of Hydroxytyrosol.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Balsalazide.Approved, Investigational
BatroxobinHydroxytyrosol may increase the anticoagulant activities of Batroxobin.Experimental
BecaplerminHydroxytyrosol may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BemiparinHydroxytyrosol may increase the anticoagulant activities of Bemiparin.Approved, Investigational
BeraprostHydroxytyrosol may increase the anticoagulant activities of Beraprost.Investigational
BivalirudinHydroxytyrosol may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BrinaseHydroxytyrosol may increase the anticoagulant activities of Brinase.Experimental
BuflomedilHydroxytyrosol may increase the antiplatelet activities of Buflomedil.Experimental
ButylphthalideButylphthalide may increase the antiplatelet activities of Hydroxytyrosol.Investigational
Calcium carbimideThe risk or severity of adverse effects can be increased when Calcium carbimide is combined with Hydroxytyrosol.Approved, Withdrawn
CangrelorHydroxytyrosol may increase the anticoagulant activities of Cangrelor.Approved
CaplacizumabHydroxytyrosol may increase the anticoagulant activities of Caplacizumab.Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Carbaspirin calcium.Experimental, Investigational
CertoparinHydroxytyrosol may increase the anticoagulant activities of Certoparin.Approved, Investigational
CilostazolHydroxytyrosol may increase the anticoagulant activities of Cilostazol.Approved, Investigational
Citric AcidHydroxytyrosol may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClopidogrelHydroxytyrosol may increase the anticoagulant activities of Clopidogrel.Approved
CloricromenHydroxytyrosol may increase the anticoagulant activities of Cloricromen.Experimental
ClorindioneHydroxytyrosol may increase the anticoagulant activities of Clorindione.Experimental
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Collagenase clostridium histolyticum.Approved, Investigational
Dabigatran etexilateHydroxytyrosol may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinHydroxytyrosol may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidHydroxytyrosol may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanHydroxytyrosol may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Hydroxytyrosol.Approved, Investigational
DefibrotideHydroxytyrosol may increase the anticoagulant activities of Defibrotide.Approved, Investigational
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Deoxycholic Acid.Approved
DersalazineThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Dersalazine.Investigational
DesirudinHydroxytyrosol may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseHydroxytyrosol may increase the anticoagulant activities of Desmoteplase.Investigational
DextranHydroxytyrosol may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
Dextran 40Hydroxytyrosol may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Hydroxytyrosol may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Hydroxytyrosol may increase the anticoagulant activities of Dextran 75.Approved
DicoumarolHydroxytyrosol may increase the anticoagulant activities of Dicoumarol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Diflunisal.Approved, Investigational
DiphenadioneHydroxytyrosol may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleHydroxytyrosol may increase the anticoagulant activities of Dipyridamole.Approved
DitazoleHydroxytyrosol may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
Drotrecogin alfaHydroxytyrosol may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
Edetic AcidHydroxytyrosol may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanHydroxytyrosol may increase the anticoagulant activities of Edoxaban.Approved
EnoxaparinHydroxytyrosol may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineEpinastine may increase the antiplatelet activities of Hydroxytyrosol.Approved, Investigational
EplivanserinHydroxytyrosol may increase the anticoagulant activities of Eplivanserin.Investigational
eplivanserineHydroxytyrosol may increase the anticoagulant activities of eplivanserine.Investigational
EpoprostenolHydroxytyrosol may increase the anticoagulant activities of Epoprostenol.Approved
EptifibatideHydroxytyrosol may increase the anticoagulant activities of Eptifibatide.Approved, Investigational
Ethyl biscoumacetateHydroxytyrosol may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ferulic acidHydroxytyrosol may increase the anticoagulant activities of Ferulic acid.Experimental
FibrinolysinHydroxytyrosol may increase the anticoagulant activities of Fibrinolysin.Investigational
FluindioneHydroxytyrosol may increase the anticoagulant activities of Fluindione.Approved, Investigational
FondaparinuxHydroxytyrosol may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumHydroxytyrosol may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
GabexateHydroxytyrosol may increase the anticoagulant activities of Gabexate.Investigational
GlucosamineGlucosamine may increase the antiplatelet activities of Hydroxytyrosol.Approved, Investigational
GuacetisalThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Guacetisal.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Hemoglobin crosfumaril.Experimental
HeparinHydroxytyrosol may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineHydroxytyrosol may increase the anticoagulant activities of Higenamine.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Hydroxytyrosol.Approved
IbudilastIbudilast may increase the antiplatelet activities of Hydroxytyrosol.Approved, Investigational
Icosapent ethylIcosapent ethyl may increase the antiplatelet activities of Hydroxytyrosol.Approved, Investigational, Nutraceutical
IdraparinuxHydroxytyrosol may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilIfenprodil may increase the antiplatelet activities of Hydroxytyrosol.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the antiplatelet activities of Hydroxytyrosol.Investigational
IloprostHydroxytyrosol may increase the anticoagulant activities of Iloprost.Approved, Investigational
IndobufenHydroxytyrosol may increase the anticoagulant activities of Indobufen.Investigational
KetanserinKetanserin may increase the antiplatelet activities of Hydroxytyrosol.Investigational
LacidipineHydroxytyrosol may increase the hypotensive activities of Lacidipine.Approved, Investigational
LepirudinHydroxytyrosol may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanHydroxytyrosol may increase the anticoagulant activities of Letaxaban.Investigational
LimaprostLimaprost may increase the antiplatelet activities of Hydroxytyrosol.Approved, Investigational
LinsidomineHydroxytyrosol may increase the antiplatelet activities of Linsidomine.Experimental
LorpiprazoleThe therapeutic efficacy of Hydroxytyrosol can be increased when used in combination with Lorpiprazole.Approved
MelagatranHydroxytyrosol may increase the anticoagulant activities of Melagatran.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Mesalazine.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Methyl salicylate.Approved, Vet Approved
MilrinoneMilrinone may increase the antiplatelet activities of Hydroxytyrosol.Approved
NadroparinHydroxytyrosol may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatHydroxytyrosol may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftopidilNaftopidil may increase the antiplatelet activities of Hydroxytyrosol.Investigational
NimesulideNimesulide may increase the antiplatelet activities of Hydroxytyrosol.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Nitroaspirin.Investigational
ObinutuzumabThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Obinutuzumab.Approved, Investigational
OlsalazineThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Olsalazine.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Hydroxytyrosol.Approved, Nutraceutical
OtamixabanHydroxytyrosol may increase the anticoagulant activities of Otamixaban.Investigational
OzagrelHydroxytyrosol may increase the anticoagulant activities of Ozagrel.Investigational
ParnaparinHydroxytyrosol may increase the anticoagulant activities of Parnaparin.Approved, Investigational
Pentaerythritol TetranitrateHydroxytyrosol may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Hydroxytyrosol.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Hydroxytyrosol.Approved, Investigational
PhenindioneHydroxytyrosol may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonHydroxytyrosol may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PicotamideHydroxytyrosol may increase the anticoagulant activities of Picotamide.Experimental
PrasugrelHydroxytyrosol may increase the anticoagulant activities of Prasugrel.Approved
Protein CHydroxytyrosol may increase the anticoagulant activities of Protein C.Approved
Protein S humanHydroxytyrosol may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeHydroxytyrosol may increase the anticoagulant activities of Protocatechualdehyde.Approved
RamatrobanHydroxytyrosol may increase the antiplatelet activities of Ramatroban.Investigational
RelcovaptanHydroxytyrosol may increase the antiplatelet activities of Relcovaptan.Investigational
ResveratrolResveratrol may increase the antiplatelet activities of Hydroxytyrosol.Approved, Experimental, Investigational
ReteplaseHydroxytyrosol may increase the anticoagulant activities of Reteplase.Approved, Investigational
ReviparinHydroxytyrosol may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelRidogrel may increase the antiplatelet activities of Hydroxytyrosol.Approved
RivaroxabanHydroxytyrosol may increase the anticoagulant activities of Rivaroxaban.Approved
RosiglitazoneHydroxytyrosol may increase the anticoagulant activities of Rosiglitazone.Approved, Investigational
Salicylic acidThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Salicylic acid.Approved, Investigational, Vet Approved
SarpogrelateHydroxytyrosol may increase the anticoagulant activities of Sarpogrelate.Investigational
SaruplaseHydroxytyrosol may increase the anticoagulant activities of Saruplase.Experimental
SelexipagHydroxytyrosol may increase the anticoagulant activities of Selexipag.Approved
SevofluraneSevoflurane may increase the antiplatelet activities of Hydroxytyrosol.Approved, Vet Approved
SRT501SRT501 may increase the antiplatelet activities of Hydroxytyrosol.Investigational
StreptokinaseHydroxytyrosol may increase the anticoagulant activities of Streptokinase.Approved, Investigational
SulodexideHydroxytyrosol may increase the anticoagulant activities of Sulodexide.Approved, Investigational
TenecteplaseHydroxytyrosol may increase the anticoagulant activities of Tenecteplase.Approved
TesmilifeneTesmilifene may increase the antiplatelet activities of Hydroxytyrosol.Investigational
TicagrelorHydroxytyrosol may increase the anticoagulant activities of Ticagrelor.Approved
TiclopidineHydroxytyrosol may increase the anticoagulant activities of Ticlopidine.Approved
TinzaparinHydroxytyrosol may increase the anticoagulant activities of Tinzaparin.Approved
TioclomarolHydroxytyrosol may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirTipranavir may increase the antiplatelet activities of Hydroxytyrosol.Approved, Investigational
TirofibanHydroxytyrosol may increase the anticoagulant activities of Tirofiban.Approved
TositumomabThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Tositumomab.Approved, Investigational
TranilastTranilast may increase the antiplatelet activities of Hydroxytyrosol.Approved, Investigational
TrapidilTrapidil may increase the antiplatelet activities of Hydroxytyrosol.Approved
TreprostinilHydroxytyrosol may increase the anticoagulant activities of Treprostinil.Approved, Investigational
TriflusalHydroxytyrosol may increase the anticoagulant activities of Triflusal.Approved, Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Trolamine salicylate.Approved
TroxerutinHydroxytyrosol may increase the anticoagulant activities of Troxerutin.Investigational
UrokinaseHydroxytyrosol may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
Vitamin EVitamin E may increase the antiplatelet activities of Hydroxytyrosol.Approved, Nutraceutical, Vet Approved
VorapaxarHydroxytyrosol may increase the anticoagulant activities of Vorapaxar.Approved
WarfarinHydroxytyrosol may increase the anticoagulant activities of Warfarin.Approved
XimelagatranHydroxytyrosol may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB05784
PubChem Compound
82755
PubChem Substance
347828956
ChemSpider
74680
ChEBI
68889
ChEMBL
CHEMBL1950045

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3RecruitingTreatmentNAFLD1
Not AvailableRecruitingPreventionCancer, Breast / Elevated Risk of Developing Breast Cancer / Family History of Breast Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility17.4 mg/mLALOGPS
logP0.13ALOGPS
logP0.89ChemAxon
logS-0.95ALOGPS
pKa (Strongest Acidic)9.45ChemAxon
pKa (Strongest Basic)-2.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area60.69 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity41.59 m3·mol-1ChemAxon
Polarizability15.74 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as tyrosols. These are organic aromatic compounds containing a phenethyl alcohol moiety that carries a hydroxyl group at the 4-position of the benzene group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenols
Sub Class
Tyrosols and derivatives
Direct Parent
Tyrosols
Alternative Parents
Catechols / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Benzene and substituted derivatives / Primary alcohols / Hydrocarbon derivatives
Substituents
Tyrosol / Catechol / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Monocyclic benzene moiety / Organic oxygen compound / Hydrocarbon derivative / Primary alcohol / Organooxygen compound / Alcohol
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
catechols, primary alcohol (CHEBI:68889)

Drug created on October 20, 2016 18:09 / Updated on November 09, 2017 05:12